BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 32825798)

  • 1. Direct Binding of Cisplatin to p22phox, an Endoplasmic Reticulum (ER) Membrane Protein, Contributes to Cisplatin Resistance in Oral Squamous Cell Carcinoma (OSCC) Cells.
    Hung CC; Li FA; Liang SS; Wang LF; Lin IL; Chiu CC; Lee CH; Chen JY
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32825798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p22phox confers resistance to cisplatin, by blocking its entry into the nucleus.
    Hung CC; Chien CY; Chiang WF; Lin CS; Hour TC; Chen HR; Wang LF; Ko JY; Chang CH; Chen JY
    Oncotarget; 2015 Feb; 6(6):4110-25. PubMed ID: 25686830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential resistance to platinum-based drugs and 5-fluorouracil in p22phox-overexpressing oral squamous cell carcinoma: Implications of alternative treatment strategies.
    Hung CC; Chien CY; Chu PY; Wu YJ; Lin CS; Huang CJ; Chan LP; Wang YY; Yuan SF; Hour TC; Chen JY
    Head Neck; 2017 Aug; 39(8):1621-1630. PubMed ID: 28498554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression.
    Fang Z; Zhao J; Xie W; Sun Q; Wang H; Qiao B
    Cancer Med; 2017 Dec; 6(12):2897-2908. PubMed ID: 29125238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNA HOXA11-AS Promotes Proliferation and Cisplatin Resistance of Oral Squamous Cell Carcinoma by Suppression of miR-214-3p Expression.
    Wang X; Li H; Shi J
    Biomed Res Int; 2019; 2019():8645153. PubMed ID: 31275988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of cisplatin cytotoxicity by SAHA involves endoplasmic reticulum stress-mediated apoptosis in oral squamous cell carcinoma cells.
    Suzuki M; Endo M; Shinohara F; Echigo S; Rikiishi H
    Cancer Chemother Pharmacol; 2009 Nov; 64(6):1115-22. PubMed ID: 19280190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of satraplatin in cisplatin-resistant oral squamous cell carcinoma cells.
    Yamano Y; Shiiba M; Negoro K; Nakatani K; Kasamatsu A; Yamatoji M; Sakuma K; Ogoshi K; Iyoda M; Shinozuka K; Yokoe H; Wada T; Fujita S; Iwasawa S; Takiguchi Y; Tanzawa H; Uzawa K
    Head Neck; 2011 Mar; 33(3):309-17. PubMed ID: 20848452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined arsenic trioxide-cisplatin treatment enhances apoptosis in oral squamous cell carcinoma cells.
    Nakaoka T; Ota A; Ono T; Karnan S; Konishi H; Furuhashi A; Ohmura Y; Yamada Y; Hosokawa Y; Kazaoka Y
    Cell Oncol (Dordr); 2014 Apr; 37(2):119-29. PubMed ID: 24599717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isomahanine induces endoplasmic reticulum stress and simultaneously triggers p38 MAPK-mediated apoptosis and autophagy in multidrug-resistant human oral squamous cell carcinoma cells.
    Utaipan T; Athipornchai A; Suksamrarn A; Chunsrivirot S; Chunglok W
    Oncol Rep; 2017 Feb; 37(2):1243-1252. PubMed ID: 28075474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of Tumor Suppressor CYLD Expression Triggers Cisplatin Resistance in Oral Squamous Cell Carcinoma.
    Suenaga N; Kuramitsu M; Komure K; Kanemaru A; Takano K; Ozeki K; Nishimura Y; Yoshida R; Nakayama H; Shinriki S; Saito H; Jono H
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31635163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Copper efflux transporter (ATP7B) contributes to the acquisition of cisplatin-resistance in human oral squamous cell lines.
    Yoshizawa K; Nozaki S; Kitahara H; Ohara T; Kato K; Kawashiri S; Yamamoto E
    Oncol Rep; 2007 Oct; 18(4):987-91. PubMed ID: 17786364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone invasion-targeted chemotherapy with a novel anionic platinum complex (3Pt) for oral squamous cell carcinoma.
    Kasahara Y; Endo K; Ueno T; Ueno H; Moriyama-Kita M; Odani A; Yoshizaki T
    Cancer Sci; 2019 Oct; 110(10):3288-3295. PubMed ID: 31348586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Supramolecular nanodrug targeting CDK4/6 overcomes BAG1 mediated cisplatin resistance in oral squamous cell carcinoma.
    Zhao B; Qin X; Fu R; Yang M; Hu X; Zhao S; Cui Y; Guo Q; Zhou W
    J Control Release; 2024 Apr; 368():623-636. PubMed ID: 38479445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silencing of GLUT-1 inhibits sensitization of oral cancer cells to cisplatin during hypoxia.
    Shimanishi M; Ogi K; Sogabe Y; Kaneko T; Dehari H; Miyazaki A; Hiratsuka H
    J Oral Pathol Med; 2013 May; 42(5):382-8. PubMed ID: 23227892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor effect of poly lactic acid nanoparticles loaded with cisplatin and chloroquine on the oral squamous cell carcinoma.
    Li Q; Liu X; Yan W; Chen Y
    Aging (Albany NY); 2020 Dec; 13(2):2593-2603. PubMed ID: 33323546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exosomes containing miR-21 transfer the characteristic of cisplatin resistance by targeting PTEN and PDCD4 in oral squamous cell carcinoma.
    Liu T; Chen G; Sun D; Lei M; Li Y; Zhou C; Li X; Xue W; Wang H; Liu C; Xu J
    Acta Biochim Biophys Sin (Shanghai); 2017 Sep; 49(9):808-816. PubMed ID: 28910982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of β-Catenin Induces Cisplatin Resistance in Oral Squamous Cell Carcinoma.
    Li L; Liu HC; Wang C; Liu X; Hu FC; Xie N; Lü L; Chen X; Huang HZ
    Biomed Res Int; 2016; 2016():5378567. PubMed ID: 27529071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor effect of a Pt-loaded nanocomposite based on graphene quantum dots combats hypoxia-induced chemoresistance of oral squamous cell carcinoma.
    Wei Z; Yin X; Cai Y; Xu W; Song C; Wang Y; Zhang J; Kang A; Wang Z; Han W
    Int J Nanomedicine; 2018; 13():1505-1524. PubMed ID: 29559779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin sensitivity of oral squamous carcinoma cells is regulated by Na+,K+-ATPase activity rather than copper-transporting P-type ATPases, ATP7A and ATP7B.
    Ahmed Z; Deyama Y; Yoshimura Y; Suzuki K
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):643-50. PubMed ID: 18545997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Hippo pathway transcriptional co-activator, YAP, confers resistance to cisplatin in human oral squamous cell carcinoma.
    Yoshikawa K; Noguchi K; Nakano Y; Yamamura M; Takaoka K; Hashimoto-Tamaoki T; Kishimoto H
    Int J Oncol; 2015; 46(6):2364-70. PubMed ID: 25846049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.